TY - JOUR
T1 - Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia
T2 - Influence of dose and stem cell source shows better outcome with rich marrow
AU - The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood and Marrow Transplantation (EBMT)
AU - Gorin, Norbert C.
AU - Labopin, Myriam
AU - Rocha, Vanderson
AU - Arcese, William
AU - Beksac, Meral
AU - Gluckman, Eliane
AU - Ringden, Olle
AU - Ruutu, Tapani
AU - Reiffers, Josy
AU - Bandini, Giuseppe
AU - Falda, Michele
AU - Zikos, Panagiotis
AU - Willemze, Roelf
AU - Frassoni, Francesco
AU - Abecasis, Manuel
AU - Abráhamová, Jitka
AU - Afanassiev, B. V.
AU - Aglietta, Massimo
AU - Alabdulaaly, Abdulaziz
AU - Aleinikova, Olga
AU - Paolo Alessandrino, E.
AU - Al Shemmari, Salem H.
AU - Amadori, D.
AU - Amadori, Sergio
AU - Amos, Toren
AU - Andolina, Marino
AU - Andreesen, Reinhard
AU - Angelucci, Emanuele
AU - Anhuf, Jürgen
AU - Arnold, Renate
AU - Arpaci, Fikret
AU - Attal, Michel
AU - Azevedo, Wellington
AU - Azim, Hamdy A.
AU - Baccarani, Michele
AU - Bacigalupo, Andrea
AU - Barbui, Tiziano
AU - Bargetzi, Mario
AU - Barnard, D. L.
AU - Bartsch, H. H.
AU - Baruchel, André
AU - Battista, Camillo
AU - Bay, Jacques Olivier
AU - Bayik, Mahmut
AU - Bazarbachi, Ali
AU - Beguin, Y.
AU - López, Jose Luis Bello
AU - Burdach, Stefan
AU - Kolb, Hans Jochem
AU - Peschel, Christian
PY - 2003/10/15
Y1 - 2003/10/15
N2 - Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 108/kg with a median of 2.7 × 108/kg. The PB cell dose ranged from 0.02 to 77 × 10 8/kg with a median of 9.3 × 108/kg. The median dose for patients receiving BM (2.7 × 108/kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich.
AB - Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 108/kg with a median of 2.7 × 108/kg. The PB cell dose ranged from 0.02 to 77 × 10 8/kg with a median of 9.3 × 108/kg. The median dose for patients receiving BM (2.7 × 108/kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich.
UR - https://www.scopus.com/pages/publications/0141889254
U2 - 10.1182/blood-2003-03-0665
DO - 10.1182/blood-2003-03-0665
M3 - Article
C2 - 12829583
AN - SCOPUS:0141889254
SN - 0006-4971
VL - 102
SP - 3043
EP - 3051
JO - Blood
JF - Blood
IS - 8
ER -
SDG 3 Good Health and Well-being